Joaquim J Ferreira1, Anne Rosser2, David Craufurd3, Ferdinando Squitieri4, Nicholas Mallard5, Bernhard Landwehrmeyer6. 1. Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal. 2. Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom. 3. University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom. 4. IRCSS Neuromed, Pozzilli, Italy. 5. Amarin Pharma Inc., Bedminster, New Jersey, USA. 6. Universitätsklinik Ulm, Ulm, Germany.
Abstract
BACKGROUND: It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45. METHODS: This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects of ethyl-EPA versus placebo on 290 subjects with mild-to-moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI). RESULTS: No significant differences in TMS-4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores. CONCLUSION: Ethyl-EPA was not beneficial in patients with HD during 6 months of placebo-controlled evaluation.
BACKGROUND: It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45. METHODS: This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects of ethyl-EPA versus placebo on 290 subjects with mild-to-moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI). RESULTS: No significant differences in TMS-4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores. CONCLUSION: Ethyl-EPA was not beneficial in patients with HD during 6 months of placebo-controlled evaluation.
Authors: Tiago A Mestre; Maria João Forjaz; Philipp Mahlknecht; Francisco Cardoso; Joaquim J Ferreira; Ralf Reilmann; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins Journal: Mov Disord Clin Pract Date: 2018-01-03
Authors: Wiebke Frank; Katrin S Lindenberg; Alzbeta Mühlbäck; Jan Lewerenz; G Bernhard Landwehrmeyer Journal: Nervenarzt Date: 2021-11-11 Impact factor: 1.297